Regression of Myelofibrosis and Osteosclerosis following Hematopoietic Cell Transplantation Assessed by Magnetic Resonance Imaging and Histologic Grading

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 12, 2006, Pages 1285-1294

  Sale, George E ^a   Deeg, H Joachim ^a   Porter, Bruce A ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b First Hill Diagnostic Imaging   (United States)

Author keywords

Hematopoietic cell transplantation; Histology; Magnetic resonance imaging; Myelofibrosis; Osteosclerosis

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FEMUR; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUMBAR SPINE; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSCLEROSIS; PELVIS; POLYCYTHEMIA VERA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; BIOPSY; BONE MARROW EXAMINATION; BONE MARROW TRANSPLANTATION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYELOFIBROSIS; ORGAN SPECIFICITY; OSTEOSCLEROSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYCYTHEMIA VERA; SEVERITY OF ILLNESS INDEX; THROMBOCYTHEMIA, HEMORRHAGIC; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33845263238     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.07.008     Document Type: Article

References (20)

1. Hoffman R. Agnogenic myeloid metaplasia. In: Hoffman R., Benz E.J., Shattil S.J., Furie B., Cohen H.J., Silberstein L.E., and McGlave P. (Eds). Hematology: Basic Principles and Practice (2000), Churchill Livingstone, New York 1172-1188
2. Tefferi A. Chronic myeloid disorders: Classification and treatment overview (review). Semin Hematol 38 suppl 2 (2001) 1-4
3. Platzbecker U., Gooley T., Anasetti C., et al. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. Leuk Lymphoma 43 (2002) 1409-1414
4. Kroger N., Zabelina T., Schieder H., et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 128 (2005) 690-697
5. Rondelli D., Barosi G., Bacigalupo A., et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 105 (2005) 4115-4119
6. Deeg H.J., Gooley T.A., Flowers M.E.D., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102 (2003) 3912-3918
7. Rajantie J., Sale G.E., Deeg H.J., et al. Adverse effect of severe marrow fibrosis on hematological recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 67 (1986) 1693-1697
8. Doney K.C., Buckner C.D., Thomas E.D., et al. Allogeneic bone marrow transplantation for chronic granulocytic leukemia. Exp Hematol 9 (1981) 966-971
9. Soll E., Massumoto C., Clift R.A., et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 86 (1995) 4667-4673
10. Guardiola P., Anderson J.E., Bandini G., et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood 93 (1999) 2831-2838
11. Bauermeister D.E. Quantitation of bone marrow reticulin-a normal range. Am J Clin Pathol 56 (1971) 24-31
12. Dekmezian R., Kantarjian H.M., Keating M.J., Talpaz M., McCredie K.B., and Freireich E.J. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 59 (1987) 1739-1743
13. Deeg H.J., Storer B.E., Boeckh M., et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 12 (2006) 573-584
14. Bornhäuser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 (2003) 820-826
15. Jurado M., Deeg H.J., Storer B., et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 8 (2002) 161-169
16. Stuart M.J., Cao T.M., Sandmaier B.M., et al. Efficacy of non-myeloablative allogeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia). Blood 102 Pt 1 (2003) 185a Abstract 644
17. Anderson J.E., Tefferi A., Craig F., et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 98 (2001) 586-593
18. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88 (1996) 1013-1018
19. Olipitz W., Beham-Schmid C., Aigner R., Raith J., Linkesch W., and Sill H. Acute myelofibrosis: multifocal bone marrow infiltration detected by scintigraphy and magnetic resonance imaging. Ann Hematol 79 (2000) 275-278
20. Gualdi G.F., Di Biasi C., Serafini G., and Casciani E. The role of MRI in the valuation of disorders involving the bone marrow. [in Italian]. Clin Ter 148 (1997) 407-417